Viewing Study NCT06739720


Ignite Creation Date: 2025-12-25 @ 4:28 AM
Ignite Modification Date: 2026-01-17 @ 4:36 AM
Study NCT ID: NCT06739720
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-12-18
First Post: 2024-12-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: RCT of Efficacy and Safety of CP003 on CFS/ME or Post-COVID Fatigue
Sponsor: The University of Hong Kong
Organization:

Study Overview

Official Title: A Randomized, Waitlist-controlled Clinical Study on the Efficacy and Safety of Lingzhi-containing Dietary Supplement CP003 on Chronic Fatigue and Post-COVID Fatigue
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are:

Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation?

Researchers will compare people taking the Lingzhi supplement to those who don't take anything (waitlist group) to see if it works.

Participants will:

* Take 5 capsules once daily for 6 weeks (or wait to start treatment if in waitlist group)
* Visit the clinic 2 times for blood tests (before and after taking the supplement)
* Complete questionnaires 3 times about their fatigue and quality of life (4 times questionnaires for waitlist group)
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: